BioMed X and Daiichi Sankyo Launch Immuno-Oncology Research Team

BioMed X, an innovation hub for pharma, has introduced a new research team at its Heidelberg institute for multispecific biologics in the field of immuno-oncology in collaboration with Daiichi Sankyo through its Daiichi Sankyo Research Institute in Munich. This new project, led by BioMed X boot camp winner Dr. Reda Benmebarek, will explore next-generation biologics as a potential strategy to transform how solid tumors are treated.

“The ability of multispecific biologics to engage multiple targets simultaneously represents a powerful strategy to overcome the limitations of conventional therapies,” explains Dr. Benmebarek. “By targeting the microenvironment with new biologic scaffolds, we aim to simultaneously recruit immune cells and activate potent immune responses that could potentially increase the efficacy of solid tumor therapy.”

“We are excited to work with Daiichi Sankyo and bring together the innovative minds of both companies to improve cancer therapy,” said Dr. Thomas Rückle, Head of Research Europe at BioMed X. “This collaboration demonstrates our commitment to developing innovative multispecific platforms that may provide more effective treatment options for patients with solid tumors.”

The new research team will join five other groups at the BioMed X Institute in Heidelberg, Germany, as well as two international teams: one at the BioMed X Institute in New Haven, Connecticut, USA and another at its XSeed Labs in Ridgefield, Connecticut, an innovation accelerator located on the campus of Boehringer Ingelheim in the USA.